NewAmsterdam Pharma pany N.V.(NAMS) - 2024 Q3 - Quarterly Results

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results – Topline data from pivotal Phase 3 TANDEM trial now expected in 4Q 2024 due to faster than expected enrollment – – On-track to report topline data from pivotal Phase 3 BROADWAY trial in 4Q 2024 – – Strong balance sheet with $422.7 million in cash as of September 30, 2024 – Naarden, the Netherlands and Miami, USA; November 6, 2024 – NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a l ...